Faeth Therapeutics is a Texas biotech developing PIKTOR, an experimental cancer drug that blocks several points in a growth pathway. FTH reports earnings on Fri, Nov 13, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 16 | Guggenheim | Initiated | Buy | |
| Sep 14 | LUCID CAPITAL MARKETS | Initiated | Buy | |
| Aug 21 | Needham | Initiated | Buy | |
| Aug 11 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 4 | Jones Trading | Initiated | Buy |
Seasonality
How FTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in FTH in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FTH is in one of them and how their past FTH trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered FTH in an article yet. Here's the latest on the wider market.
About Faeth Therapeutics
Faeth Therapeutics is a biotechnology company based in Austin, Texas, that develops cancer treatments. Its lead candidate, PIKTOR, is an oral combination of two drugs designed to block several points in a cell signaling pathway that drives the growth of many solid tumors. PIKTOR is being studied in endometrial cancer and breast cancer, and the company's products are still in clinical trials. The company aims its work at patients with these cancers, based on the idea that blocking more than one point in the pathway may work better than blocking a single point.
- Headquarters
- Austin, TX